 |
|
Benefit of chemotherapy in breast cancer depends on estrogen-receptor status
April 12, 2006HOUSTON-When it comes to chemotherapy treatment for women whose breast cancer has spread to their lymph nodes, the estrogen status of their tumors matters, says a team of researchers in the April 12 issue of the Journal of the American Medical Association.
Analyzing data from three clinical trials with a total of 6,644 patients, they determined that chemotherapy works much better in breast cancer that is estrogen receptor-negative (ER-) than many people think, and conversely, doesn't work as well in estrogen receptor-positive (ER+) cancer as believed, says the study's lead author Donald Berry, Ph.D., chair of the Department of Biostatistics and Applied Mathematics at The University of Texas M. D. Anderson Cancer Center.
This conclusion will come as a surprise to many oncologists, Berry says. Women with "node-positive" breast cancer routinely are given chemotherapy, regardless of their tumor type. Women who have ER+ tumors are also given tamoxifen, a drug which inhibits estrogen use by the cancer cells.
"Our analysis shows that tamoxifen works very well for a number of years and taken as a group, there is little or no benefit of even the cumulative effects of modern improvements in chemotherapy for women with ER+ tumors," he says.
"All in all, this is good news because it shows that the benefit of chemotherapy for ER- tumors is surprisingly dramatic in the same way that tamoxifen's effect is substantial for ER+ tumors," Berry says.
The research team, which includes investigators from top cancer centers nationwide, studied outcomes from three large randomized clinical trials which tested the optimal use of chemotherapy in node-positive breast cancer. But none of these trials, all of which were conducted by the Cancer and Leukemia Group B and the U.S. Breast Intergroup, considered estrogen status or whether women had received tamoxifen, largely because the diagnostic importance of estrogen status for chemotherapy was not recognized at the time the trials were designed, Berry says.
Accumulated evidence indicates, however, that improvements in chemotherapy disproportionately benefit women with ER- tumors, Berry says; so the research team decided to statistically model the relative contribution of chemotherapy treatment given estrogen receptor status.
They found the absolute benefits due to chemotherapy were greater for patients with ER- tumors compared to those with ER+ tumors. Specifically, 22.8 percent more ER- patients were disease-free after five years if they received chemotherapy versus 7 percent of ER+ patients. The corresponding improvements for overall survival were 16.7 percent versus 4 percent.
The researchers also compared the different chemotherapy regimens tested in the trials, and found the latest chemotherapy combination studied-biweekly doxorubicin/cyclophosphamide plus paclitaxel-lowered the rate of recurrence and death in ER- patients by more than 50 percent, compared to the low-dose regimen used in the first study.
"This tells us that breast oncology has made enormous strides in treating patients with ER- tumors, a finding which contradicts the prevailing wisdom that with the development of tamoxifen and newer selective estrogen receptor modulator drugs, the benefits of medical science have been primarily focused on ER+ tumors," Berry says.
"It is true that tamoxifen changed the landscape for ER+ tumors, but the playing field has now been leveled somewhat given the fact that ER- tumors respond well to modern improvements in chemotherapy regimens," he says.
University of Texas M. D. Anderson Cancer Center
"Our analysis shows that tamoxifen works very well for a number of years and taken as a group, there is little or no benefit of even the cumulative effects of modern improvements in chemotherapy for women with ER+ tumors," he says.
"All in all, this is good news because it shows that the benefit of chemotherapy for ER- tumors is surprisingly dramatic in the same way that tamoxifen's effect is substantial for ER+ tumors," Berry says.
The research team, which includes investigators from top cancer centers nationwide, studied outcomes from three large randomized clinical trials which tested the optimal use of chemotherapy in node-positive breast cancer. But none of these trials, all of which were conducted by the Cancer and Leukemia Group B and the U.S. Breast Intergroup, considered estrogen status or whether women had received tamoxifen, largely because the diagnostic importance of estrogen status for chemotherapy was not recognized at the time the trials were designed, Berry says.
Accumulated evidence indicates, however, that improvements in chemotherapy disproportionately benefit women with ER- tumors, Berry says; so the research team decided to statistically model the relative contribution of chemotherapy treatment given estrogen receptor status.
They found the absolute benefits due to chemotherapy were greater for patients with ER- tumors compared to those with ER+ tumors. Specifically, 22.8 percent more ER- patients were disease-free after five years if they received chemotherapy versus 7 percent of ER+ patients. The corresponding improvements for overall survival were 16.7 percent versus 4 percent.
The researchers also compared the different chemotherapy regimens tested in the trials, and found the latest chemotherapy combination studied-biweekly doxorubicin/cyclophosphamide plus paclitaxel-lowered the rate of recurrence and death in ER- patients by more than 50 percent, compared to the low-dose regimen used in the first study.
"This tells us that breast oncology has made enormous strides in treating patients with ER- tumors, a finding which contradicts the prevailing wisdom that with the development of tamoxifen and newer selective estrogen receptor modulator drugs, the benefits of medical science have been primarily focused on ER+ tumors," Berry says.
"It is true that tamoxifen changed the landscape for ER+ tumors, but the playing field has now been leveled somewhat given the fact that ER- tumors respond well to modern improvements in chemotherapy regimens," he says.
University of Texas M. D. Anderson Cancer Center
Chemotherapy News and Current Chemotherapy Events RSSInternational team reveals first prognosticator of survival in aggressive cancer
The tumor suppressor gene pRb2/p130 may provide the first independent prognostic biomarker in cases of soft tissue sarcoma (STS).
NC State Is First University in Nation to Offer Canine Bone Marrow Transplants
Dogs suffering from lymphoma will be able to receive the same type of medical treatment as their human counterparts, as North Carolina State University becomes the first university in the nation to offer canine bone marrow transplants in a clinical setting.
New nano device detects immune system cell signaling
Scientists have detected previously unnoticed chemical signals that individual cells in the immune system use to communicate with each other over short distances.
Barrow researchers identify a new approach to detect the early progression of brain tumors
Researchers at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center recently participated in a pilot study with the Montreal Neurological Institute that suggests a certain type of MRI scanning can detect when a patient is failing brain tumor treatment before symptoms appear.
Variation of normal protein could be key to resistance to common cancer drug
Researchers at the Moores Cancer Center at the University of California, San Diego (UC SD) in La Jolla have found evidence explaining why a common chemotherapy drug, cisplatin, may not always work for every cancer patient. They have shown that when a variant version of a key protein that normally causes cell death is active, patients may be resistant to the cancer-killing drug.
Normalizing tumor vessels to improve cancer therapy
Chemotherapy drugs often never reach the tumors they're intended to treat, and radiation therapy is not always effective, because the blood vessels feeding the tumors are abnormal-"leaky and twisty" in the words of the late Judah Folkman, MD, founder of the Vascular Biology program at Children's Hospital Boston.
UTMB researchers test new vaccine to fight multiple influenza strains
A universal vaccine effective against several strains of influenza has passed its first phase of testing, according to Dr. Christine Turley of the University of Texas at Galveston.
Drugs to inhibit blood vessel growth show promise in rat model of deadly brain tumor
In a landmark study, Medical College of Wisconsin researchers in Milwaukee report that drugs used to inhibit a specific fatty acid in rat brains with glioblastoma-like tumors not only reduced new blood vessel growth and tumor size dramatically, but also prolonged survival. The study is the featured cover story of the August, 2008 Journal of Cerebral Blood Flow & Metabolism.
Bowel cancer indicator should lead to better treatment
STEM cell scientists have developed a more accurate way of identifying aggressive forms of bowel cancer, which should eventually lead to better treatment and survival rates.
Stem cell indicator for bowel cancer should lead to better survival rates
Stem cell scientists have developed a more accurate way of identifying aggressive forms of bowel cancer, which should eventually lead to better treatment and survival rates. Bowel cancer is the third most common cancer in the UK.
More Chemotherapy News Articles
 | Pharmacotherapy: A Pathophysiologic Approach by Joseph T. DiPiro, Robert L. Talbert, Gary C. Yee, Gary R. Matzke, Barbara G. Wells, L. Michael Posey The benchmark evidence-based pharmacotherapy text-now in full color! Additional chapters are available online When it comes to helping you develop a mastery of evidence-based medicine for optimal patient outcomes, no book can match Pharmacotherapy: A Pathophysiologic Approach. Like the discipline it covers, the scope of this trusted resource goes beyond drug indications and dosages to... |
 | Arriving at Your Own Door: 108 Lessons in Mindfulness by Jon Kabat-zinn Mindfulness opens us up to the possibility of being fully human as we are, and of expressing the humane in our way of being. Mindlessness de facto closes us up and denies us the fullness of our being alive. This book may on the surface appear to be merely another offering in the genre of daily readings. But deep within these 108 selections lie messages of profound wisdom in a contemporary and... |
 | The Clinical Drug Therapy: Rationales for Nursing Practice (Field Guide Series) by Anne Collins Abrams, Sandra Smith Pennington, Carol Barnett Lammon This popular core nursing pharmacology textbook provides unique coverage of nursing interventions for drug therapy with related rationales. Highly praised for its organized and readable presentation, the text explains the "why" behind each nursing action and emphasizes how drugs work differently in different patients. New to the Eighth Edition are case studies integrated into each chapter with... |
 | Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (Essential Psychopharmacology Series) by Stephen M. Stahl Essential. Trusted. Indispensable. Stahl's Essential Psychopharmacology has established itself as the preeminent source of education and information in its field. This much-expanded third edition relies on advances in neurobiology and recent clinical developments to explain the concepts underlying drug treatment of psychiatric disorders. In addition to redrawn art, an improved and more... |
 | Drug Therapy in Nursing by Diane S Aschenbrenner, Samantha J Venable This text presents a totally nursing-focused framework for teaching and learning nursing pharmacology, and "places the patient" at the center of all drug and drug administration decisions and considerations. The book presents core drug knowledge using prototypes of different drug classes and emphasizes core patient variables that influence the patient's response to therapy. Features include... |
 | Coming to Our Senses: Healing Ourselves and the World Through Mindfulness by Jon Kabat-zinn Ten years ago, Jon Kabat-Zinn changed the way we thought about awareness in everyday life with his now-classic introduction to mindfulness, Wherever You Go, There You Are. Now, with Coming to Our Senses, he provides the definitive book for our time on the connection between mindfulness and our physical and spiritual well-being. With scientific rigor, poetic deftness, and compelling personal... |
 | Pharmacotherapy Handbook (PHARMACOTHERAPY HANDBOOK) by Barbara G. Wells, Joseph T. DiPiro, Terry L. Schwinghammer, Cindy Hamilton The second edition of the Pharmacotherapy Handbook provides readers with a portable, readable guide that is integral to any clinical setting. Bold-face type highlights drug names when they first appear and in all closing information. The book's bulleted format helps readers find the information they need immediately. This updated book was designed as a companion text for the fourth edition... |
 | Acid-Base, Fluids, and Electrolytes Made Ridiculously Simple (MedMaster Series) by Richard Arthur Preston A brief, highly readable book providing the clinician with a straightforward approach to solving even the most complex, acid-base, fluid, and electrolyte problems. Useful to medical students, interns and residents, nurses responsible for IV fluid therapy, and first year nephrology... |
 | Pharmacotherapy Principles & Practice by Marie A. Chisholm-Burns, Barbara G. Wells, Terry L. Schwinghammer, Patrick M. Malone, Jill M. Kolesar, John C. Rotschafer, Joseph T. DiPiro Easy-to-follow disorder-based organization that surveys the full range of organ system disorders treated in pharmacy practice Knowledge-building boxed features within chapters, consisting of: Clinical Presentation & Diagnosis, Patient Encounters, and Patient Care and Monitoring Guidelines A standardized chapter format Laboratory values expressed in both conventional units and Systemé... |
 | Pharmacotherapeutics for Advanced Practice: A Practical Approach by Virginia Poole Arcangelo, Andrew M Peterson This advanced pharmacotherapeutics text for nurse practitioners and physician assistants offers guidelines on prescribing drugs for over 50 common diseases and disorders. The book is organized by disorder rather than drug class and includes algorithms and case studies that illustrate critical thinking aspects of prescribing, such as drug selection, lifespan considerations, therapeutic drug... |
| © 2008 BrightSurf.com |